Scotland follows NICE with no to Novartis's Afinitor and Celgene's Vidaza
This article was originally published in Scrip
The Scottish Medicines Consortium, Scotland's health technology appraisal body, said on 12 April that it would not be recommending Novartis's Afinitor (everolimus) for the treatment of advanced renal cell carcinoma (RCC) or Celgene's Vidaza (azacitidine) for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia on the Scottish NHS.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.